The Conversation (0)
Leap Therapeutics entered a clinical trial collaboration agreement with Merck to research a drug treatment combination for patients with relapsed or refractory advanced esophagogastric cancers.
Leap Therapeutics (NASDAQ:LPTX) entered a clinical trial collaboration agreement with Merck (NYSE:MRK) to research a drug treatment combination for patients with relapsed or refractory advanced esophagogastric cancers.
As quoted in the press release:
“This clinical collaboration with Merck is the first of the combination immunotherapy studies we plan to initiate in each of our two programs, DKN-01 and TRX518. Combining DKN-01 with KEYTRUDA has a strong scientific rationale and offers hope to patients with few treatment options,” commented Cynthia Sirard, M.D., Vice President, Clinical Development of Leap Therapeutics.
The study is expected to begin enrolling patients in the second-half of 2017. The collaboration agreement is between Leap and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.
Click here to read the full press release.
Source: globenewswire.com